Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 12, 2010 Selena Maranjian	Don't Underestimate These Great Stocks Companies with rock-bottom P/Es could be true bargains.
The Motley Fool August 16, 2010 Dan Caplinger	Don't Ignore These Cheap Stocks Values abound. Don't miss the boat.
Registered Rep. November 24, 2010 Diana Britton	Stampede Out Of Municipal Bonds Is Temporary; Reversal Ahead Record municipal bond outflows last week represent a short-term blip in the market, some industry sources say.
The Motley Fool June 20, 2011 Selena Maranjian	Are These Stocks Your Best Defense? Are telecom and semiconductor companies the new soap makers and drugmakers?
The Motley Fool November 30, 2010 Amanda B. Kish	Did the Bond Bubble Just Pop? Bonds may be the new black for investors, but it looks like fashion trends may be changing in the upcoming season.
The Motley Fool August 13, 2010 Amanda B. Kish	Must-Read Mutual Fund News The week's happenings in the mutual fund industry.
The Motley Fool October 6, 2010 Amanda B. Kish	More Top Investments for Your Retirement Cover your retirement bases with some familiar fund names: Vanguard 500 Index... State Street Global S&P 500 Index... American Funds EuroPacific Growth... PIMCO Total Return... American Funds Growth Fund of America...
Financial Advisor October 2012 Michelle Knight	A Great Reallocation? The long predicted shift from bonds to equities could finally happen.
The Motley Fool February 9, 2011 Amanda B. Kish	Investors Are Still Chasing Returns Wise up. Bonds probably aren't the best place for your money.
The Motley Fool May 11, 2010 Morgan Housel	Buffett, Munger, and Exploding Markets Low interest rates haven't lured investors back in.
The Motley Fool March 22, 2010 Brian Orelli	Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio.
The Motley Fool November 1, 2010 Eric Bleeker	Cirrus Logic Is a Chip Leader Why I'll be purchasing shares of Cirrus Logic.
Registered Rep. November 16, 2010 Stan Luxenberg	Winning Mutual Fund Strategy: Buy the Unloved Sectors This year, the most unpopular category is large growth, which recorded outflows of $39 billion during the 12 months ending in August. Other unpopular categories are large value and world stock.
The Motley Fool February 3, 2010 Dan Caplinger	5 Boring Stocks That Won't Let You Down Don't take chances with your wealth. The easy money has been made, and so those who expect to duplicate those returns year in and year out are deluding themselves.
The Motley Fool September 30, 2010 Matt Koppenheffer	5 Stocks That Still Have Single-Digit P/Es The market may not be as cheap as it was, but these stocks are still bargains.
The Motley Fool February 28, 2011 Cindy Johnson	Medicis Pharmaceutical Shares Popped: What You Need to Know Medicis Pharmaceutical Corporation popped 26% in intraday trading today after reporting an inline quarter and announcing a licensing agreement with Teva Pharmaceutical Industries.
The Motley Fool May 3, 2007	Teva Pharmaceutical Has Strong Quarter: Fool by Numbers The pharmaceutical released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
Registered Rep. March 1, 2007	International Flight Over the last three years, foreign mutual funds have posted annual returns twice those notched by the S&P 500, prompting investors to dump shares of U.S. stock funds and park that cash overseas in search of fatter returns.
The Motley Fool February 14, 2011 Dan Caplinger	It's Not Too Late to Run This Bull Just because stocks are at multiyear highs doesn't mean you should stay on the sidelines.
The Motley Fool September 17, 2010 Anand Chokkavelu	How Expensive Is Cirrus Logic Stock by the Numbers? Let's see what the numbers can tell us about how cheap integrated circuit maker Cirrus Logic might be.
The Motley Fool November 17, 2009 Amanda B. Kish	American Funds' Achilles' Heel Why is the fund giant losing money to competitors?
Registered Rep. October 21, 2010 Stan Luxenberg	Investors, Drunk on Bonds, Should Be Soberly Searching for Unloved Categories Shareholders have been buying bonds and dumping stock funds for months -- even when the markets have been improving. Will investors regain their old appetite for stock funds any time soon?
Financial Planning February 1, 2012 Donna Mitchell	Optimism Reigns Mutual fund investors were an optimistic bunch in the fourth quarter. They clung to hopes of a U.S. economic recovery, even after enduring lots of bumps and two major shocks that left the S&P 500 up just 5.8% for the quarter, a shadow of the strong 10.8% from the same period a year earlier.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
The Motley Fool May 18, 2010 Brian Orelli	Price Inflation in Check? Not in This Industry. Drug prices are on the rise. For now.
The Motley Fool August 8, 2011 Sean Williams	6 Stocks You Can Buy Right Now These companies could be the right combination to turn an aching portfolio around
The Motley Fool January 31, 2008 Brian Orelli	Wyeth Calls Teva's Bluff Wyeth launches a generic version of its own heartburn drug.
The Motley Fool June 30, 2005 Brian Gorman	The Co-Pay Effect Higher co-payments look like the wave of the future, and investors should expect the trend to boost major generic players like Teva Pharmaceutical, Mylan Laboratories, and Novartis.
The Motley Fool January 13, 2011 Selena Maranjian	Follow These Target-Date Funds' Lead Don't miss out on turbocharged economic growth.
The Motley Fool February 15, 2005 Stephen D. Simpson	Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma.
The Motley Fool December 8, 2010 Dan Caplinger	Are U.S. Investors Coming Home? ETF flows are starting to change direction.
The Motley Fool July 30, 2010 Anand Chokkavelu	5 Stocks to Consider Before Buying Pfizer If you like Pfizer, you may like these five insurance and medical stocks better.
The Motley Fool September 14, 2009 Dan Caplinger	This Will Still Help You Retire Rich People are laying blame in the wrong place. The mistake that most people made wasn't in using target funds. Instead, they should have understood the risk they were taking.
The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool February 27, 2007 Dan Caplinger	Paying for Quality With bonds, sometimes it pays to get the best. Investors and mutual funds that are buying lower-quality bonds may find that they would've been better off sticking with Treasuries in the long run.
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.
The Motley Fool June 22, 2006 Stephen D. Simpson	Merck Goes on the Attack Predator becomes prey in this latest twist in the generics game. Given how much the markets hate uncertainty, that could mean that big generic drug companies might go on sale for patient long-term investors.
The Motley Fool January 13, 2011 Anders Bylund	Memory or Electronics -- Who Do You Love? The computer memory industry stands at a crossroads, and analysts can't agree on where it's going. Will 2011 be a year of feast or famine?
National Real Estate Investor December 1, 2005 Anthony Downs	Awash In Capital, But For How Long? It is time both to enjoy the success of real estate while it lasts, and also to prepare for a not-so-distant moment when its attraction compared to stocks and bonds grows considerably weaker.
The Motley Fool April 7, 2010 Rick Steier	Is Teva Pharmaceutical a Forever Hold? Teva is a compelling reason why investors should look abroad for opportunity.
The Motley Fool November 8, 2006 Brian Lawler	Teva Is Rolling in Cash Again Investors, the bottom line is that with 13 proprietary drugs in phase 2 trials or later for some very large indications, plus 144 applications to sell generic versions of branded drugs waiting at the FDA, Teva's near-term future is strong.
The Motley Fool October 5, 2011 Dan Caplinger	Has Teva Pharmaceutical Become the Perfect Stock? Teva still looks poised to stay near perfection for the indefinite future.
The Motley Fool December 2, 2008 Bruce Jackson	This Recession's One Shining Light The bad economic news is likely to keep coming for a while yet. On the bright side, it gives you plenty of time to pick up stock market bargains.
The Motley Fool October 16, 2009 Amanda B. Kish	The Next Investment Bubble If you're simply following the crowd because you think bonds are the place to be right now, be careful. This corner of the market may be getting pretty inflated and could very well let investors down.
The Motley Fool September 27, 2010 Amanda B. Kish	Will Your Bond Fund Blow Up? Consider the risks.
The Motley Fool July 14, 2010 Dan Caplinger	How to Play 2010's Hot Stock Trends The second quarter created headwinds, but some investors have still profited.
Registered Rep. February 26, 2013 Diana Britton	Deja Vu The stampede from U.S. equity mutual funds and the accompanying positive S&P 500 performance over the last few years is eerily similar to the late 1970s' bull market, a new report by The Leuthold Group says.
The Motley Fool January 5, 2004 Mathew Emmert	Broken Bonds Even if you've just experienced a painful breakup with the stock market, don't go falling in love with bonds just because you're on the rebound. The plain truth is that looking for love in today's bond market could lead to another broken heart.
Registered Rep. January 27, 2011 Stan Luxenberg	Don't Dump Your Muni Mutual Funds The municipal default rate remains tiny, and yields on high-quality bonds are relatively rich.
InternetNews December 17, 2007 Paul Shread	Adobe Starts Big Earnings Week On An Up Note Adobe got an important week for the stock market off to a solid start with a stellar earnings report... Rambus gained on a licensing deal with Toshiba... Amazon fell on reports of weaker than expected online sales... etc.